Keywords: AE; adverse event; ADR; adverse drug reaction; ANC; absolute neutrophil count; CI; confidence interval; CR; complete remission; CTCAE; common terminology criteria for adverse events; DEX; dexamethasone; ECOG; eastern cooperative oncology group; eCRF; elec
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ASCT; autologous stem cell transplant; CR; complete response; CT; computed tomography; DPd; daratumumab, pomalidomide, and dexamethasone; DRd; daratumumab, lenalidomide, and dexamethasone; DVd; daratumumab, bortezomib, and dexamethasone; ERd; elotuzumab,
Keywords: ASCT; autologous stem cell transplant; EMD; extramedullary disease; FLC; free light chain; ISS; International Staging System; KRD; carfilzomib, lenalidomide, and dexamethasone; MGUS; monoclonal gammopathy of undetermined significance; MM; multiple myeloma
Keywords: AH; amyloid heavy chain; AL; amyloid light chain; ASCT; autologous stem cell transplant; ATTR; amyloid transthyretin; B-Dex; bortezomib and dexamethasone; BMDex; bortezomib plus melphalan and dexamethasone; BNP; brain natriuretic peptide; Bor; bortezomib;
Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma
Keywords: AL; light chain; BM; bone marrow; CI; confidence interval; CR; complete response; FA; fat aspirate; HDT; high-dose therapy; MM; multiple myeloma; OS; overall survival; PBSCT; peripheral blood stem cell transplant; PR; partial response; SD; stable disease;
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Keywords: CCT; conventional chemotherapy; CR; complete response; dex; dexamethasone; EFS; event-free survival; FISH; fluorescence in situ hybridization; HDM; high-dose melphalan; IMiD; immunomodulatory drug; ISS; International Staging System; MGUS; monoclonal gammo
Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
Keywords: CI; confidence interval; CR; complete response; ECOG; Eastern Cooperative Oncology Group; G-CSF; granulocyte colony-stimulating factor; OS; overall survival; PFS; progression-free survival; PR; partial response; Rev-Dex; lenalidomide and dexamethasone; SC
Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma
Keywords: CR; complete response; DVd; pegylated liposomal doxorubicin, vincristine, and decreased-frequency dexamethasone; IQR; interquartile range; OS; overall survival; PFS; progression-free survival; SWOG; Southwest Oncology Group; VGPR; very good partial respon